Ocumetics Technology Corp · TSXV:OTC
Ocumetics Technology — Investor Presentation (November 2025)
19 slides from Ocumetics Technology's investor presentation, November 2025
Slide 1: Accommodating Intraocular Lens Designed To Replicate Natural Vision
Accommodating Intraocular Lens Designed To Replicate Natural Vision ocumetics.com TSXV: OTC.V FSE: 2QB0 OTCQB: OTCFF 1
Slide 2: Disclaimer
DISCLAIMER Nothing contained in this presentation is or shall be relied upon as a promise, guarantee, representation of or warranty specific or implied as to future performance of Ocumetics Technology Corp. The forward-looking statements contained in this presentation are expressly qualified in thei
Slide 3: The Opportunity
THE OPPORTUNITY Breakthrough Innovation Strong Leadership ● Successful First-In-Human (FIH) implants - August 2025 ● CEO Dean Burns: ex-Alcon Vision ($750M BU, 15 FDA ● Designed for rapid, dynamic focus – near to far in <1 approvals, $6B in product launches) second ● Backed by 12 leading ophthalmolo
Slide 4: The Problem
THE PROBLEM About Site loss with Age 83% Adults aged 45 and older in The eye deteriorates as we age, developing the following conditions: the U.S. experience ● Presbyopia (age 45+): Loss of accommodation – inability to focus presbyopia ● Cataracts (age 65+): Cloudy, inflexible natural – blindness if
Slide 5: The Solution
THE SOLUTION No Silicone Oil Chamber Biometric Vision Restoration ● Designed to avoid fragile silicone oil ● Designed to restore biometric vision chambers used in competitor implants, ● Designed to replicate natural eye biomechanics using preventing leakage, clouding, and long- shape-changing lens t
Slide 6: What Is The Natural Lens Biokinetics?
WHAT IS THE NATURAL LENS BIOKINETICS? Instant Dynamic Focusing ● Shifts focus from near to far in under one second, ensuring seamless clarity for reading, driving, or distance viewing Tense Relaxed Non-Accommodated Accommodated Tense muscles & attachments Relaxed muscles & attachments What is Accomm
Slide 7: Strong Global IP
STRONG GLOBAL IP 49 Global Patents 3 Provisional 46 Utility UNITED STATES FDA REST OF WORLD ● The Food and Drug Administration (FDA) Centre for Devices and Radiological ● Each country or jurisdiction has a regulatory body similar Health (CDRH) is responsible for regulatory firms who manufacture, rep
Slide 8: Successfully Implanted – August 15, 2025
SUCCESSFULLY IMPLANTED – AUGUST 15, 2025 Four Hours Post Surgery First two patients successfully received the Ocumetics Lens 69 79 yrs old yrs old First Human Patients Tense Relaxed Close up of eye during surgery with outline of the Ocumetics Lens Accommodating Intraocular Lens Designed To Replicate
Slide 9: Accommodating Intraocular Lens (IOL) Competition
ACCOMMODATING INTRAOCULAR LENS (IOL) COMPETITION Atia ● Shape-changing, fluid filled based with fixed-power anterior optic for target refraction ● FIH clinical data 2023 ● FDA multi-phase study (2026–28) Alcon Fluid Vision ● Silicone oil-filled haptics ● Accommodative effort moves fluid from haptics
Slide 10: IOL Technology Analysis
IOL TECHNOLOGY ANALYSIS Technology Distance Intermediate Near Side Effects Monofocal No Extended Depth of No Focus Bifocal Yes* Trifocal Yes* Ocumetic Lens No * Side effects = Halos, ghosting, starbursts and light scatter Accommodating Intraocular Lens Designed To Replicate Natural Vision 10
Slide 11: Market Analysis
MARKET ANALYSIS Ocumetics’ strategy is to initially enter the $1.2Bn, 65+ Cataract surgery segment $4.5B Ocumetics has a pipeline of lenses designed to address the larger markets Total Intraocular Lens Market Premium IOL (45+Only) Segment $1.7B Premium IOL (65+Only) Segment $1.2B Accommodating Intra
Slide 12: Procedure Analysis
PROCEDURE ANALYSIS US 3.5 – 4.0M Procedures Annually US PROCEDURES/YR Most recent ophthalmology and cataract surgery statistics put the U.S. volume at ~3.7–4.1 million cataract surgeries per year. The figure matches industry sources (e.g., American Academy of Ophthalmology, Market Scope). 3.5-4M 3 –
Slide 13: Acquisitions By Majors
ACQUISITIONS BY MAJORS Of Less Advanced Ocular Technologies Development Stage at Acquisition Company Technology Focus(2) Acquirer Year Status Acquisition Value (USD)(1) + up to $135M $285M milestones PowerVision Silicone oil-based AIOL Preclinical Alcon 2019 upfront (2) FIH Clinical trials paused Sy
Slide 14: Current Clinical Milestones
CURRENT CLINICAL MILESTONES First-In-Human 30 Patient Study Milestone Estimates FIH Group 2 Submit FDA (6 months) Regulatory Documents FIH Group 1 FIH Group 3 (6 months) (6 months) Q1 Q3 Q3/Q4 2026 Q2 2026 2025 2026 Focus Safety, Distance, and Focus Near Focus Safety, Safety and Distance Distance, N
Slide 15: Corporate Structure
CORPORATE STRUCTURE Shares Outstanding 125,754,391 5,241,850 ($0.125/Apr 27/26) Options 5,753,850 512,000 ($0.32/Jun 12/28) Restricted Share Units Subject to Performance Milestones 5,000,000 416,600 ($0.64/Jan 15/26) Warrants 1,317,730 901,130 ($0.50/Nov 10/25) Convertible Debentures $4M @ 0.32 - 18
Slide 16: Dean Burns
DEAN BURNS Dean Burns CEO, President & Director Former Senior Director at Alcon Vision, managing a $750M business unit across devices, disposables, intraocular lenses (IOLs), and pharmaceuticals. Successfully led 15 FDA approvals and 15 product launches with a combined $6B commercial value, while pa
Slide 17: Management & Directors
MANAGEMENT & DIRECTORS Roger Jewett CA, CPA Dr. Garth Webb Dr. Doyle Stulting CFO & Director Founder, CSO & Director Chief Medical Officer & Director With over 25 years of experience leading public and He is the Founder of Ocumetics and sole inventor He is a renowned corneal surgeon and recognized g
Slide 18: Management & Directors
MANAGEMENT & DIRECTORS Dr. James B McRoberts,O.D. Michael Edwards Robert Quinn Director Director Director With over 40 years of experience in optometry, He is a Director at Pinnacle Wealth Brokers, one of He is an independent businessman with extensive board, including private practice in British Co
Slide 19: Contact Information
CONTACT INFORMATION Contact: Website: Address: Dave Burwell ocumetics.com 639 5 Ave SW #1250 Director, Investor Relations Calgary, AB 403-410-7907 T2P 0M9 dave.burwell@ocumetics.com Canada TSXV: OTC.V FSE: 2QB0 OTCQB: OTCFF Accommodating Intraocular Lens Designed To Replicate Natural Vision 19
Ocumetics Technology — Investor Presentation (November 2025) on 6ix